Design and Pharmaceutical Applications of Prodrugs

Drug Discovery Handbook

Volumn , Issue , 2005, Pages 733-796

  Järvinen, Tomi ^a   Rautio, Jarkko ^a   Masson, Mar ^b   Loftsson, Thorsteinn ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Double prodrug; Low molecular weight prodrugs; Prodrug approach

Indexed keywords

EID: 40149093335     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0471728780.ch17     Document Type: Chapter

References (182)

1. Venkatesh, S., Lipper,R. A. (2000). Role of the development scientist in the compound lead selection and optimization. J. Pharm. Sci., 89, 145-154.
2. Alber, A. (1958). Chemical aspects of selective toxicity. Nature, 16, 421-423.
3. Krise, J. P., Stella, V. J. (2003). Prodrugs: A year of renewed interest in an old concept. AAPS Newsmag., 16, 25.
4. Stella,V. J., Charman,W. N. A., Naringrekar,V. H. (1985). Prodrugs. Do they have advantages in clinical practice? Drugs, 29, 455-473.
5. Leppänen, J., Huuskonen, J., Nevalainen, T., Gynther, J., Taipale, H., Järvinen, T. (2002). Design and synthesis of a novel L-dopa-entacapone codrugs. J. Med. Chem., 45, 1379-1382.
6. Stella, V. J. (1996). A case for prodrugs: Fosphenytoin. Adv. Drug Delivery Rev., 19, 311-330.
7. Shaw, J. P., Sueoko,C. M., Oliyai, R., Lee,W. A., Arimilli, M. N., Kim,C. U., Cundy, K. C. (1997). Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm. Res., 14, 1824-1829.
8. Bundgaard, H., Falch, E., Larsen, C., Mosher, G. L., Mikkelson, T. J. (1986). Pilocarpine prodrugs II: Synthesis, stability, bioconversion, and physicochemical properties of sequentially labile pilocarpine acid diesters. J. Pharm. Sci., 75, 775-783.
9. Thorsteinsson,T., Loftsson,T., Masson, M. (2003). Soft antibacterial agents. Curr. Med. Chem., 10, 1129-1136.
10. Bodor, N., Buchwald, P. (1997). Drug targeting via retrometabolic approaches. Pharmacol. Ther., 76, 1-27.
11. Bodor, N., Buchwald, P. (2000). Soft drug design: General principals and recent applications. Med. Res. Rev., 20, 58-101.
12. Bodor, N. (1985). Prodrugs versus soft drugs. In H. Bundgaard (Ed.), Design of Prodrugs. Elsevier Science, Amsterdam, pp. 333-354.
13. Amidon, G. L., Lennernas, H., Shah,V. P., Crison, J. R. (1995). A theoretical basis for a bipharmaceutic classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12, 413-420.
14. Bundgaard, H. (1985). Formation of prodrugs of amines, amides, ureides, and imides. Methods Enzymol., 112, 347-359.
15. Fleisher, D., Bong, R., Stewart, B. H. (1996). Improved oral drug delivery: Solubility limitations overcome by the use of prodrugs. Adv. Drug Delivery Rev., 19, 115-130.
16. Taylor, M. D. (1996). Improved passive oral drug delivery via prodrugs. Adv. Drug Delivery Rev., 19, 131-148.
17. Haeberlin, B., Rubas,W., Nolen, H. W., Friend, D. R. (1993). In-vitro evaluation of dexamethasone-beta-d-glucuronide for colon-specific drug-delivery. Pharm. Res., 10, 1553-1562.
18. Chourasia, M. K., Jain, S. K. (2003). Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci., 6, 33-66.
19. Cabri,W., Di Fabio, R. (2000). From Bench to Market. Oxford University Press, Oxford, p. 148.
20. Prokai, L., Prokai-Tatarai, K. (1999). In P. K. Gupta and G. A. Brazeau (Eds.), Prodrugs. Injectable Drug Development.Techniques to Reduce Pain and Irritation. Interpharm, Denver, CO, pp. 267-306.
21. Sinkula, A. A., Yalkowsky, S. H. (1975). Rationale for design of biologically reversible drug derivatives-prodrugs. J. Pharm. Sci., 64, 181-210.
22. Menard, J., Patchett,A. A. (2001). Angiotensin-converting enzyme inhibitors. Adv. Protein Chem., 56, 13-75.
23. Tammara, V. K., Narurkar, M. M., Crider, A. M., Khan, M. A. (1993). Synthesis and evaluation of morpholinoalkyl ester prodrugs of indomethacin and naproxen. Pharm. Res., 10, 1191-1199.
24. Rautio, J., Taipale, H., Gynther, J., Vepsäläinen, J., Nevalainen, T., Järvinen, T. (1998). In vitro evaluation of acyloxyalkyl esters as dermal prodrugs of ketoprofen and naproxen. J. Pharm. Sci., 87, 1622-1628.
25. Ferres, H. (1983). Pro-drugs of b-lactam antibiotics. Drugs of Today, 19, 499-538.
26. Shanbhag, V. R., Crider, A. M., Gokhale, R., Harpalani, A., Dick, R. M. (1992). Ester and amide prodrugs of ibuprofen and naproxen-Synthesis, antiinflammatory activity, and gastrointestinal toxicity. J. Pharm. Sci., 81, 149-154.
27. Krise, J. P., Stella, V. J. (1996). Prodrugs of phosphates, phosphonates, and phosphinates. Adv. Drug Delivery Rev., 19, 287-310.
28. McGuigan, C., Turner, S., Nicholls, S. R., Oconnor, T. J., Kinchington, D. (1994). Haloalkyl phosphate derivatives of act as inhibitors of HIV-Studies in the phosphate region. Antiviral Chem. Chemother., 5, 162-168.
29. Schott, H., Ludwig, P. S., Immelmann, A., Schwendener, R. A. (1999). Synthesis and in vitro anti-HIV activities of amphiphilic heterodinucleoside phosphate derivatives containing the 2¢,3¢-dideoxynucleosides ddC, AZT and ddI. Eur. J. Med. Chem., 34, 343-352.
30. Pompon, A., Lefebvre, I., Imbach, J. L., Kahn, S., Farquhar, D. (1994). Decomposition pathways of the mono-(pivaloyl-oxymethyl) and bis(pivaloyl-oxymethyl) esters of azidothymidine 5¢-monophosphate in cell extract and in tissue-culture medium-An application of the online Isrp-cleaning HPLC technique. Antiviral Chem. Chemother., 5, 91-98.
31. Hostetler, K. Y., Parker, S., Sridhar, C. N., Martin, M. J., Li, J. L., Stuhmiller, L. M., Vanwijk, G. M. T., Vandenbosch, H., Gardner, M. F., Aldern, K. A., Richman, D. D. (1993). Acyclovir diphosphate dimyristoylglycerol-A phospholipid prodrug with activity against acyclovir-resistant herpes-simplex virus. Proc. Nat. Acad. Sci. USA, 90, 11,835-11,839.
32. Saboulard, D., Naesens, L., Cahard, D., Salgado, A., Pathirana, R., Velazquez, S., McGuigan, C., De Clercq, E., Balzarini, J. (1999). Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine. Mol. Pharmacol., 56, 693-704.
33. Serafinowska, H. T., Ashton, R. J., Bailey, S., Harnden, M. R., Jackson, S. M., Sutton, D. (1995). Synthesis and in vivo evaluation of prodrugs of 9-[2-(phosphonomethoxy) ethoxy]adenine. J. Med. Chem., 38, 1372-1379.
34. Starrett, J. E. Jr, Tortolani, D. R., Russell, J., Hitchcock, M. J., Whiterock, V., Martin, J. C., Mansuri, M. M. (1994). Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy) ethyl]adenine (PMEA). J. Med. Chem., 37, 1857-1864.
35. Delombaert, S., Erion, M. D., Tan, J., Blanchard, L., Elchehabi, L., Ghai, R. D., Sakane, Y., Berry, C., Trapani, A. J. (1994). N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new-generation of neutral endopeptidase (Nep, Ec-3.4.24.11) inhibitors. J. Med. Chem., 37, 498-511.
36. Niemi, R., Vepsäläinen, J., Taipale, H., Järvinen, T. (1999). Bisphosphonate prodrugs: Synthesis and in vitro evaluation of novel acyloxyalkyl esters of clodronic acid. J. Med. Chem., 42, 5053-5058.
37. Niemi, R., Pennanen, H.,Vepsäläinen, J., Taipale, H., Järvinen, T. (1998). Bisphosphonate prodrugs: Synthesis and in vitro evaluation of novel partial amides of clodronic acid. Int. J. Pharm., 174, 111-115.
38. Larsen, C., Johansen, M. (1987). Macromolecular prodrugs. 4. Kinetics of hydrolysis of metronidazole monosuccinate dextran ester conjugates in aqueoussolution and in plasma-Sequential release of metronidazole from the conjugates at physiological pH. Int. J. Pharm., 35, 39-45.
39. Mollmann, H., Rohdewald, P., Barth, J., Mollmann, C., Verho, M., Derendorf, H. (1988). Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high-doses. Pharm. Res., 5, 509-513.
40. Kong,A. N., Jusko,W. J. (1991). Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats-Nonlinear and sequential 1st-pass elimination. J. Pharm. Sci., 80, 409-415.
41. Bundgaard, H., Larsen, C.,Thorbek, P. (1984). Prodrugs as drug delivery systems. 26. Preparation and enzymatic-hydrolysis of various water-soluble amino-acid esters of metronidazole. Int. J. Pharm., 18, 67-77.
42. Mahfouz, N. M., Hassan, M. A. (2001). Synthesis, chemical and enzymatic hydrolysis, and bioavailability evaluation in rabbits of metronidazole amino acid ester prodrugs with enhanced water solubility. J. Pharm. Pharm., 53, 841-848.
43. Másson, M., Thorsteinsson, T., Sigurdsson, T. H., Loftsson, T. (2000). Lipophilic metronidazole derivatives and their absoprtion through hairless mouse skin. Die Pharmazie, 55, 369-371.
44. Ueda,Y., Matiskella, J. D., Mikkilineni, A. B., Farina,V., Knipe, J. O., Rose,W. C., Casazza, A. M., Vyas,D. M. (1995). Novel, water-soluble phosphate derivatives of 2¢-ethoxy carbonylpaclitaxel as potential prodrugs of paclitaxel-Synthesis and antitumor evaluation. Bioorganic Med. Chem. Lett., 5, 247-252.
45. Sawada, S., Yaegashi, T., Furuta, T., Yokokura, T., Miyasaka, T. (1993). Chemical modification of an antitumor alkaloid, 20(S)-camptothecin-E-lactone ringmodified water-soluble derivatives of 7-ethylcamptothecin. Chem. Pharm. Bull., 41, 310-313.
46. Yaegashi,T., Sawada, S., Nagata, H., Furuta,T.,Yokokura,T., Miyasaka,T. (1994). Synthesis and antitumor-activity of 20(S)-camptothecin derivatives-A-ringsubstituted 7-ethylcamptothecins and their E-ring-modified water-soluble derivatives. Chem. Pharm. Bull., 42, 2518-2525.
47. Bodor, N., Sloan, K. B., Higuchi, T., Sasahara, K. (1977). Improved delivery through biological-membranes. 4. Prodrugs of L-dopa. J. Med. Chem., 20, 1435-1445.
48. Johansen, M., Bundgaard, H. (1980). Pro-drugs as drug delivery systems. 13. Kinetics of decomposition of N-Mannich bases of salicylamide and assessment of their suitability as possible pro-drugs for amines. Int. J. Pharm., 7, 119-127.
49. Bundgaard, H., Johansen, M., Stella, V., Cortese, M. (1982). Pro-drugs as drug delivery systems. 21. Preparation, physicochemical properties and bioavailability of a novel water-soluble pro-drug type for carbamazepine. Int. J. Pharm., 10, 181-192.
50. Redden, R., Douglas, J. E., Burke, M. J., Horrobin, D. F. (1998). In vitro hydrolysis of polyunsaturated fatty acid N-acyloxymethyl derivatives of theophylline. Int. J. Pharm., 165, 87.
51. Bundgaard, H., Falch, E., Jensen, E. (1989). A novel solution-stable, water-soluble prodrug type for drugs containing a hydroxyl or an NH-acidic group. J. Med. Chem., 32, 2503-2507.
52. Sloan, K. B., Hashida, M., Alexander, J., Bodor, N., Higuchi, T. (1983). Prodrugs of 6-thiopurines-Enhanced delivery through the skin. J. Pharm. Sci., 72, 372-378.
53. Mollgaard, B., Hoelgaard, A., Bundgaard, H. (1982). Pro-drugs as drug delivery systems. 23. Improved dermal delivery of 5-fluorouracil through human-skin via N-acyloxymethyl pro-drug derivatives. Int. J. Pharm., 12, 153-162.
54. Yang, C.,Tirucherai,G. S., Mitra, A. K. (2001). Prodrug based optimal drug delivery via membrane transporter/receptor. Expert Opin. Biol. Ther., 1, 159-175.
55. Shaw, J. P., Sueoka,C. M., Oliyai, R., Lee,W. A., Arimilli, M. N., Kim,C. U., Cundy, K. C. (1997). Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm. Res., 14, 1824-1829.
56. Gallant, J. E., Deresinski, S. (2003). Tenofovir disoproxil fumarate. Clin. Infect. Dis., 37, 944-950.
57. Cundy, K. C., Barditch-Crovo, P.,Walker, R. E., Collier, A. C., Ebeling, D., Toole, J., Jaffe, H. S. (1995). Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother., 39, 2401-2405.
58. Gustafsson, D. (2003). Oral direct thrombin inhibitors in clinical development. J. Internal Med., 254, 322-334.
59. Han, H. K., Amidon, G. L. (2000). Targeted prodrug design to optimize drug delivery. AAPS PharmSci, 2, E6.
60. Steffansen, B., Nielsen, C. U., Brodin, B., Eriksson, A. H., Andersen, R., Frokjaer, S. (2004). Intestinal solute carriers: An overview of trends and strategies for improving oral drug absorption. Eur. J. Pharm. Sci., 21, 3-16
61. de Miranda, P., Good, S. S. (1992). Species differences in the metabolism and disposition of antiviral nucleoside analogues: 1. Acyclovir. Antiviral Chem. Chemother., 3, 1-8.
62. Weller, S., Blum, M. R., Doucette, M., Burnette,T., Cederberg,D. M., De Miranda, P., Smiley, M. L. (1993). Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers. Clin. Pharm. Ther., 54, 595-605.
63. Beutner, K. R., Friedman, D. J., Forszpaniak, C., Andersen, P. L., Wood, M. J. (1995). Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother., 39, 1546-1553.
64. Guo, A., Hu, P., Balimane, P. V., Leibach, F. H., Sinko, P. J. (1999). Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J. Pharmcol. Exper. Ther., 289, 448-454.
65. Han, H., De Vrueh, R. L., Rhie, J. K., Covitz, K. M., Smith, P. L., Lee, C. P., Oh, D. M., Sadee, W., Amidon, G. L. (1998). 5¢-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res., 15, 1154-1159.
66. Sugawara, M., Huang, W., Fei, Y. J., Leibach, F. H., Ganapathy, V., Ganapathy, M. E. (2000). Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci., 89, 781-789.
67. Heimbach, T., Oh, D. M., Li, L. Y., Forsberg, M., Savolainen, J., Leppanen, J., Matsunaga,Y., Flynn,G., Fleisher,D. (2003). Absorption rate limit considerations for oral phosphate prodrugs. Pharm. Res., 20, 848-856.
68. Li, Y. H., Ito, K., Tsuda, Y., Kohda, R., Yamada, H., Itoh, T. (1999). Mechanism of intestinal absorption of an orally active beta-lactam prodrug: Uptake and transport of carindacillin in Caco-2 cells. J. Pharmcol. Exper. Ther., 290, 958-964.
69. Sloan, K. B.,Wasdo, S. (2003). Designing for topical delivery: Prodrugs can make the difference. Med. Res. Rev., 23, 763-793.
70. Sloan, K. B. (1989). Prodrugs for dermal delivery. Adv. Drug Delivery Rev., 3, 67-101.
71. Sloan, K. B. (1992). Functional group considerations in the development of prodrugs approaches to solving topical delivery problems. In K. B. Sloan (Ed.), Prodrugs; Topical and Ocular Drug Delivery. Marcel Dekker, New York, pp. 17-116.
72. Chien, Y. W. (1983). Logics of transdermal controlled drug administration. Drug Devel. Ind. Pharm., 9, 497-520.
73. Rautio, J., Nevalainen, T., Taipale, H., Vepsäläinen, J., Gynther, J., Pedersen, T., Järvinen, T. (1999). Synthesis and in vitro evaluation of aminoacyloxyalkyl esters of 2-(6-methoxy-2-naphthyl)propionic acid as novel naproxen prodrugs for dermal drug delivery. Pharm. Res., 16, 1172-1178.
74. Rautio, J., Nevalainen, T., Taipale, H., Vepsäläinen, J., Gynther, J., Laine, K., Järvinen, T. (2000). Synthesis and in vitro evaluation of novel morpholinyl-and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy-2-naphthyl)propionic acid (naproxen) for topical drug delivery. J. Med. Chem., 43, 1489-1494.
75. Rautio, J., Nevalainen, T., Taipale, H., Vepsäläinen, J., Gynther, J., Laine, K., Järvinen, T. (2000). Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. Eur. J. Pharm. Sci., 11, 157-163.
76. Udata, C.,Tirucherai,G., Mitra, A. K. (1999). Synthesis, stereoselective enzymatic hydrolysis, and skin permeation of diastereomeric propranolol ester prodrugs. J. Pharm. Sci., 88, 544-550.
77. Doane, M. G., Jensen, A. D., Dohlman, C. H. (1978). Penetration routes of topically applied eye medications. Am. J. Ophthalmol., 85, 383-386.
78. Rojanasakul, Y., Wang, L-Y., Bhat, M., Glover, D. D., Malanga, C. J., Ma, K. H. (1992). The transport barrier of epithelia:A comparative study on membrane permeability and charge selectivity in the rabbit. Pharm. Res., 9, 1029-1034.
79. Chien, D-S., Sasaki, H., Bundgaard, H., Buur, A., Lee, V. H. L. (1991). Role of enzymatic lability in the corneal and conjunctival penetration on timolol ester prodrugs in the pigmented rabbit. Pharm. Res., 8, 728-733.
80. Wang,W., Sasaki, H., Chien,D.-S., Lee,V. H., L. (1991). Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit:A comparison with corneal penetration. Curr. Eye Res., 10, 571-579.
81. Schoenwald, R. D., Huang, H.-S. (1983). Corneal penetration behavior of betablocking agents I: Physicochemical factors. J. Pharm. Sci., 72, 1266-1272.
82. Schoenwald, R. D.,Ward, R. L. (1978). Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients. J. Pharm. Sci., 67, 787-789.
83. Sasaki, H., Yamamura, M., Mukai, T., Nishida, K., Nakamura, J., Nakashima, M., Ichikawa, M. (1999). Enhancement of ocular drug penetration. Crit. Rev. Ther. Drug Carrier Syst., 16, 85-146.
84. Hussain,A.,Truelove, J. E. (1976). Prodrug approaches to enhancement of physicochemical properties of drugs IV: Novel epinephrine prodrug. J. Pharm. Sci., 65, 1510-1512.
85. Anderson, J. A. (1980). Systemic absorption of topical ocularly applied epinephrine and dipivefrin. Arch. Ophthalmol., 98, 350-353.
86. Mandell, A. I., Stentz, F. (1978). Dipivalyl epinephrine: A new pro-drug in the treatment of glaucoma. Ophthalmology, 85, 268-275.
87. Wei, C., Anderson, J. A., Leopold, I. (1978). Ocular absorption and metabolism of topically applied epinephrine and a dipivalyl ester of epinephrine. Investigative Ophthalmol. Vis. Sci., 17, 315-321.
88. Kaback, M. B., Podos, S. M., Harbin, Jr. T. S., Mandell, A., Becker, B. (1976). The effects of dipivalyl epinephrine on the eye. Am. J. Ophthalmol., 81, 768-772.
89. Kohn, A. N., Moss, A. P., Hargett, N. A., Ritch, R., Smith, H., Podos, S. M. (1979). Clinical comparison of dipivalyl epinephrine and epinephrine in the treatment of glaucoma. Am. J. Ophthalmol., 87, 196-201.
90. Susanna, R., Chew, P., Kitazawa, Y. (2002). Current status of prostaglandin therapy; Latanoprost and unoprostone. Surv. Ophthalmol., 47, S97-S104.
91. Netlans,P. A., Landry,T., Sullivan, E. K.,Andrew, R., Silver, L.,Weiner,A., Mallick, S., Dickerson, J., Bergamini,W.V.W., Robertson, S. M., Davis,A. D. (2001). Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol., 132, 472-484.
92. Suhonen, P., Järvinen, T., Lehmussaari, K., Reunamäki, T., Urtti A. (1996). Rate control of ocular pilocarpine delivery with bispilocarpic acid diesters. Int. J. Pharm., 127, 85-94.
93. Chang, S.-C., Bundgaard, H., Buur, A., Lee, V. H. L. (1988). Low dose O-butyryl timolol improves the therapeutic index of timolol in the pigmented rabbit. Investigative Ophthalmol. Vis. Sci., 29, 626-629.
94. Sasaki, H., Igarashi, Y., Nishida, K., Nakamura, J. (1993). Ocular delivery of the b-blocker, tilisolol, through the prodrug approach. Int. J. Pharm., 93, 49-60.
95. Anand, B. S., Mitra, A. K. (2002). Mechanism of corneal permeation of l-valyl ester of acyclovir: Targeting the oligopeptide transporter on the rabbit cornea. Pharm. Res., 19, 1194-1202.
96. Washington,N.,Washington,C.,Wilson,C. G. (2001). Nasal drug delivery. In Physiological Pharmaceutics. Barriers to Drug Absorption, 2nd ed., Taylor & Francis, London, pp. 199-220.
97. Pezron, I.,Tirucherai, G. S., Duvvuri, S., Mitra, A. K. (2002). Prodrug strategies in nasal drug delivery. Expert Opin. Ther. Patents, 12, 331-340.
98. Hussain, A. A., Al-Bayatti, A. A., Dakkuri, A., Okochi, K., Hussain, M. A. (2002). Testosterone 17b-N,N-dimethylglycinate hydrochloride: A prodrug with a potential for nasal delivery of testosterone. J. Pharm. Sci., 91, 785-789.
99. Loftsson, T., Gudmundsdottir, H., Sigurjonsdottir, J. F., Sigurdsson, H. H., Sigfusson, S. D., Masson, M., Stefansson, E. (2001). Cyclodextrin solubilization of benzodiazepines: Formulation of midazolam nasal spray. Int. J. Pharm., 212, 29-40.
100. Gudmundsdottir, H., Sigurjonsdottir, J. F., Masson, M., Fjalldal,O., Stefansson, E., Loftsson, T. (2001). Intranasal administration of midazolam in a cyclodextrin based formulation: Bioavailability and clinical evaluation in humans. Pharmazie, 56, 963-966.
101. Cox, D. S., Raje, S., Gao, H. L., Salama, N. N., Eddington, N. D. (2002). Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin. Pharm. Res., 19, 1680-1688.
102. Shao, Z., Hoffman, A. J., Mitra, A. K. (1994). Biodegradation characteristics of acyclovir 2¢-esters by respiratory carboxylesterases: Implications in prodrug design for intranasal and pulmonary drug delivery. Int. J. Pharm., 112, 181-190.
103. Shao, Z., Park, G.-B., Krishnamoorthy, R., Mitra, A. K. (1994). The physicochemical properties, plasma enzymatic hydrolysis, and nasal absorption of acyclovir and its 2¢-ester prodrugs. Pharm. Res., 11, 237-242.
104. Hussain, A. A. (1998). Intranasal drug delivery. Adv. Drug Delivery Rev., 29, 39-49.
105. Kao,H. D.,Traboulsi, A., Itoh, S., Dittert, L., Hussain, A. (2000). Enhancement of systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm. Res., 17, 978-984.
106. Yang, C., Mitra, A. K. (2001). Nasal absorption of tyrosine-linked model compounds. J. Pharm. Sci., 90, 340-347.
107. Yang, C., Gao, H., Mitra, A. K. (2001). Chemical stability, enzymatic hydrolysis, and nasal uptake of amino acid ester prodrugs of acyclovir. J. Pharm. Sci., 90, 617-624.
108. Rasmussen, G. J., Bundgaard, H. (1991). Prodrugs of peptides. 15. 4-Imidazolidinone prodrug derivatives of enkephalins to prevent aminopeptidasecatalyzed metabolism in plasma and absorptive mucosae. Int. J. Pharm., 76, 113-122.
109. Tirucherai, G. S., Pezron, I., Mitra, A. K. (2002). Novel approaches to nasal delivery of peptides and proteins. S. T.P. Pharma Sci., 12, 3-12.
110. Witterland, A. H. I., Koks, C. H. W., Beijnen, J. H. (1996). Etoposide phosphate, the water soluble prodrug of etoposide. Pharm.World Sci., 18, 163-170.
111. Krise, J. P., Narisawa, S., Stella,V. J. (1999). A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected Nphosphonooxymethyl prodrugs. J. Pharm. Sci., 88, 922-927.
112. Krise, J. P., Charman,W. N., Charman, S. A., Stella, V. J. (1999). A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs. J. Pharm. Sci., 88, 928-932.
113. Krise, J. P., Zygmunt, J., Georg, G. I., Stella, V. J. (1999). Novel prodrug approach for tertiary amines: Synthesis and preliminary evaluation of Nphosphonooxymethyl prodrugs. J. Med. Chem., 42, 3094-3100.
114. Larsen, C.,Kurtzhals, P., Johansen, M. (1988). Kinetics of regeneration of metronidazole from hemiesters of maleic acid, succinic acid and glutaric acid in aqueous buffer, human plasma and pig liver homogenate. Int. J. Pharm., 41, 121-129.
115. Robinson, R. P., Reiter, L. A., Barth,W. E., Campeta, A. M., Cooper, K., Cronin, B. J., Destito, R., Donahue, K. M., Falkner, F. C., Fiese, E. F., Johnson, D. L., Kuperman, A. V., Liston, T. E., Malloy, D., Martin, J. J., Mitchell, D. Y., Rusek, F. W., Shamblin, S. L., Wright, C. F. (1996). Discovery of the hemifumarate and (alpha-l-alanyloxy)methyl ether as prodrugs of an antirheumatic oxindole: Prodrugs for the enolic OH group. J. Med. Chem., 39, 10-18.
116. Hendler, S. S., Sanchez, R. A., Zielinski, J. (2001). Water soluble pro-drugs of propofol. U. S. Patent 6,254,853 B1.
117. Hudkins, R. L., Iqbal, M., Park, C. H., Goldstein, J., Herman, J. L., Shek, E., Murakata, C., Mallamo, J. P. (1998). Prodrug esters of the indolocarbazole CEP-751 (KT-6587). Bioorganic Med. Chem. Lett., 8, 1873-1876.
118. Bradshaw, T. D., Chua, M. S., Browne, H. L., Trapani,V., Sausville, E. A., Stevens, M. F. (2002). In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Br. J. Cancer, 86, 1348-1354.
119. Nam, N. H., Kim,Y.,You,Y. J., Hong, D. H., Kim, H. M., Ahn, B. Z. (2003).Water soluble prodrugs of the antitumor agent 3-(3-amino-4-methoxy)phenyl]-2-(3,4,5-trimethoxyphenyl)cyclopent-2-ene-1-one. Bioorganic Med. Chem., 11, 1021-1029.
120. Marder, S. R., Aravagiri, M.,Wirshing,W. C.,Wirshing, D. A., Lebell, M., Mintz, J. (2002). Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. Schizophr. Res., 53, 25-30.
121. Shechter, Y., Tsubery, H., Fridkin, M. (2003). Suspensions of pro-drug insulin greatly prolong normoglycemic patterns in diabetic rats. Biochem. Biophys. Res. Commun., 307, 315-321.
122. Svensson, L. A.,Tunek,A. (1988). The design and bioactivation of presystemically stable prodrugs. Drug Metabolism Rev., 19, 165-194.
123. Tunek, A., Levin, E., Svensson, L. A. (1988). Hydrolysis of 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro. Biochem. Pharmcol., 37, 3867-3876.
124. Sinhababu,A. K.,Thakker,D. R. (1996). Prodrugs of anticancer agents. Adv. Drug Delivery Rev., 19, 241-273.
125. Brown, J. M., Giaccia,A. J. (1998). The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res., 58, 408-416.
126. Naylor, M. A., Thomson, P. (2001). Recent advances in bioreductive drug targeting. Mini Rev. Med. Chem., 1, 17-29.
127. Wardman, P., Dennis, M. F., Everett, S. A., Patel, K. B., Stratford, M. R., Tracy, M. (1995). Radicals from one-electron reduction of nitro compounds, aromatic Noxides and quinones: The kinetic basis for hypoxia-selective, bioreductive drugs. Biochem. Soc. Symp., 61, 171-194.
128. Xu,G., McLeod, H. L. (2001). Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res., 7, 3314-3324.
129. Jung, M. (2001). Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy. Mini Rev. Med. Chem., 1, 399-407.
130. Aghi, M., Hochberg, F., Breakefield, X. O. (2000). Prodrug activation enzymes in cancer gene therapy. J. Gene Med., 2, 148-164.
131. Chen, L.,Waxman,D. J. (2002). Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr. Pharm. Des., 8, 1405-1416.
132. Niculescu-Duvaz, I., Spooner, R., Marais, R., Springer, C. J. (1998). Gene-directed enzyme prodrug therapy. Bioconjugate Chem., 9, 4-22.
133. Springer, C. J., Niculescu-Duvaz, I. (2000). Approaches to gene-directed enzyme prodrug therapy (GDEPT). Adv. Exper. Med. Biol., 465, 403-409.
134. Genka, S., Deutsch, J., Shetty, U. H., Stahle, P. L., John, V., Lieberburg, I. M., Ali-Osman, F., Rapoport, S. I, Greig, N. H. (1993). Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil. Clin. Exper. Metastasis, 11, 131-140.
135. Greig, N. H., Genka, S., Daly, E. M., Sweeney,D. J., Rapoport, S. I. (1990). Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration. Cancer Chemother. Pharmcol., 25, 311-319.
136. Bodor, N., Buchwald, P. (1999). Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Delivery Rev., 36, 229-254.
137. Bodor, N., Buchwald, P. (2002). Barriers to remember: Brain-targeting chemical delivery systems and Alzheimeŕs disease. Drug Discov. Today, 7, 766-774.
138. Tsuji, A., Tamai, I. I. (1999). Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Delivery Rev., 5, 277-290.
139. Tamai, I., Tsuji, A.(2000). Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci., 89, 1371-1388.
140. Halmos, T., Santarromana, M., Antonakis, K., Scherman, D. (1996). Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter. Eur. J. Pharmcol., 318, 477-484.
141. Bonina, F. P., Arenare, L., Palagiano, F., Saija, A., Nava, F., Trombetta, D., De Caprariis, P. (1999). Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs. J. Pharm. Sci., 88, 561-567.
142. Battaglia,G., La Russa, M., Bruno,V.,Arenare, L., Ippolito, R., Copani,A., Bonina, F., Nicoletti, F. (2000). Systemically administered d-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain Res., 860, 149-156.
143. Manfredini, S., Pavan, B.,Vertuani, S., Scaglianti, M., Compagnone,D., Biondi, C., Scatturin, A., Tanganelli, S., Ferraro, L., Prasad, P., Dalpiaz, A. (2002). Design, synthesis and activity of ascorbic acid prodrugs of nipecotic, kynurenic and diclophenamic acids, liable to increase neurotropic activity. J. Med. Chem., 45, 559-562.
144. Kearney, A. S. (1996). Prodrugs and targeted drug delivery. Adv. Drug Delivery Rev., 19, 225-239.
145. Chourasia, M. K., Jain, S. K. (2003). Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci., 6, 33-66.
146. Haas, M., Moolenaar, F., Meijer, D. K., De Zeeuw, D. (2002). Specific drug delivery to the kidney. Cardiovasc. Drugs Ther., 16, 489-496.
147. Wilk, S., Mizoguchi, H., Orlowski, M. (1978). g-Glutamyl dopa: A kidney-specific dopamine precursor. J. Pharmcol. Exper. Ther., 206, 227-232.
148. Orlowski, M., Mizoguchi, H.,Wilk, S. (1980). N-acyl-gamma-glutamyl derivatives of sulfamethoxazole as models of kidney-selective prodrugs. J. Pharmcol. Exper. Ther., 212, 167-172.
149. Lee, M. R. (1990). Five years' experience with gamma-l-glutamyl-l-dopa: A relatively renally specific dopaminergic prodrug in man. J.Autonomic Pharmcol., 10, 103-108.
150. Gangwar, S., Pauletti, G. M.,Wang, B. H., Siahaan, T. J., Stella, V. J., Borchardt, R. T. (1997). Prodrug strategies to enhance the intestinal absorption of peptides. Drug Discov. Today, 2, 148-155.
151. Borchardt, R. T. (1999). Optimizing oral absorption of peptides using prodrug strategies. J. Controlled Release, 62, 231-238.
152. Ripka, A. S., Rich, D. H. (1998). Peptidomimetic design. Curr. Opin. Chem. Biol., 2, 441-452.
153. Oliyai, R. (1996). Prodrugs of peptides and peptidomimetics for improved formulation and delivery. Adv. Drug Delivery Rev., 19, 275-286.
154. Oliyai, R., Stella, V. J. (1992). Kinetics and mechanism of isomerization of cyclosporine-A. Pharm. Res., 9, 617-622.
155. Hamada,Y.,Matsumoto, H., Kimura,T., Hayashi,Y., Kiso,Y. (2003). Effect of the acyl groups on O ÆN acyl migration in the water-soluble prodrugs of HIV-1 protease inhibitor. Bioorganic Med. Chem. Lett., 13, 2727-2730.
156. Hamada, Y., Ohtake, J., Sohma, Y., Kimura, T., Hayashi, Y., Kiso, Y. (2002). New water-soluble prodrugs of HIV protease inhibitors based on O Æ N intramolecular acyl migration. Bioorganic Med. Chem., 10, 4155-4167.
157. Bundgaard, H. (1992). The utility of the prodrug approach to improve peptide absorption. J. Controlled Release, 21, 63-72.
158. Delie, F., Couvreur, P., Nisato,D., Michel, J. B., Puisieux, F., Letourneux,Y. (1994). Synthesis and in-vitro study of a diglyceride prodrug of a peptide. Pharm. Res., 11, 1082-1087.
159. Friis,G. J. (2000). Peptide and protein derivatives. In S. Frokjaer and L. Hovgaard (Eds.), Pharmaceutical. Formulation Development of Peptides and Proteins.Taylor & Francis, London, pp. 206-219.
160. Kahns, A. H., Buur, A., Bundgaard, H. (1993). Prodrugs of peptides. 18. Synthesis and evaluation of various esters of desmopressin (Ddavp). Pharm. Res., 10, 68-74.
161. Gudmundsson, O. S., Jois, S. D. S., Vander Velde, D. G., Siahaan, T. J.,Wang, B., Borchardt, R. T. (1999). The effect of conformation on the membrane permeation of coumarinic acid-, and phenylpropionic acid-based cyclic prodrugs of opioid peptides. J. Peptide Res., 53, 383-392.
162. Bak, A., Gudmundsson, O. S., Friis, G. J., Siahaan, T. J., Borchardt, R. T. (1999). Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: Evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers. Pharm. Res., 16, 24-29.
163. Gudmundsson,O. S.,Nimkar, K., Gangwar, S., Siahaan,T., Borchardt, R. T. (1999). Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation. Pharm. Res., 16, 16-23.
164. Chang, S.-C., Bundgaard, H., Buur,A., Lee,V. H. L. (1987). Improved corneal penetration of timolol by prodrugs as a means to reduce systemic drug load. Investigative Ophthalmol. Vis. Sci., 29, 487-491.
165. Mahmud,T., Rafi, S. S., Scott,D. L., Wriilesworth, J. M., Bjarnason, I. (1996). Nonsteroidal antiiflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum., 39, 1998-2003.
166. Ogiso,T., Iwaki, M.,Tanino,T., Nagai,T., Ueda,Y., Muraoka,O.,Tanabe,G. (1996). Pharmacokinetics of indomethacin ester prodrugs: Gastrointestinal and hepatic toxicity and the hydrolytic capacity of various tissues in rats. Biol. Pharm. Bull., 19, 1178-1183.
167. Samara, E.,Avnir, D., Ladkani, D., Bialer, M. (1995). Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen. Biopharm. Drug Disposition, 16, 201-210.
168. Bonina, F., Trombetta, D., Borzi, A., De Pasquale, A., Saija, A. (1997). 1-Ethylazacycloalkan-2-one indomethacin esters as new oral prodrugs: Chemical stability, enzymatic hydrolysis, anti-inflammatory activity and gastrointestinal toxicity. Int. J. Pharm., 156, 245-250.
169. Jaksic, P., Mlinaric-Majerski, K., Zorc, B., Dumic, M. (1996). Macromolecular prodrugs. VI. Kinetic study of poly[a,b-(N-2-hydroxyethyl-dl-aspartamide]-ketoprofen hydrolysis. Int. J. Pharm., 135, 177-182.
170. Mahfouz, N. M., Omar, F. A., Aboul-Fadl, T. (1999). Cyclic amide derivatives as potential prodrugs II: N-hydroxymethylsuccinimide-/istatin esters of some NSAIDs as prodrugs with an improved therapeutic index. Eur. J. Med. Chem., 34, 551-562.
171. Duncan, R., Gac-Breton, S., Keane, R., Musila, R., Sat,Y. N., Satchi, R., Searle, F. (2001). Polymer-drug conjugates, PDEPT and PELT: Basic principles for design and transfer from the laboratory to clinic. J. Controlled Release, 74, 135-146.
172. Bickel, U.,Yoshikawa, T., Pardridge,W. M. (2001). Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Delivery Rev., 46, 247-279.
173. Mehvar, R. (2000). Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J. Controlled Release, 69, 1-25.
174. Lovrek, M., Zorc, B., Boneschans, B., Butula, I. (2000). Macromolecular prodrugs. VIII. Synthesis of polymer-gemfibrozil conjugates. Int. J. Pharm., 200, 59-66
175. Van Der Merwe, T., Boneschans, B., Zorc, B., Breytenbach, J., Zovko, M. (2002). Macromolecular prodrugs: X. Kinetics of fenoprofen release from PHEAfenoprofen conjugate. Int. J. Pharm., 241, 223-230.
176. Li, C. (2002). Poly(l-glutamic acid)-Anticancer drug conjugates. Adv. Drug Delivery Rev., 54, 695-713.
177. Kopecek, J.,Kopeckova, P.,Minko,T., Lu, Z. (2000). HPMA copolymer-anticancer drug conjugates: Design, activity, and mechanism of action. Eur. J. Pharm. Biopharm., 50, 61-81.
178. Maeda, H., Sawa, T., Konno, T. (2001). Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Controlled Release, 74, 47-61.
179. Maeda, H. (2001). SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv. Drug Delivery Rev., 46, 169-185.
180. Greenwald, R. B., Conover, C. D., Choe,Y. H. (2000). Poly(ethylene glycol) conjugated drugs and prodrugs:A comprehensive review. Crit. Rev.Ther. Drug Carrier Sys., 17, 101-161.
181. Greenwald, R. B. (2001). PEG drugs: An overview. J. Controlled Release, 74, 159-171.
182. Greenwald, R. B., Choe,Y. H., McGuire, J., Conover, C. D. (2003). Effective drug delivery by PEGylated drug conjugates. Adv. Drug Delivery Rev., 55, 217-250.